Skip to main content

Table 1 Baseline characteristics

From: Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy

  N  
Age (years) 28 52.5 (22–75; 20.0)
Sex (female), n (%) 28 26 (92.9)
Weight (kg) 28 75.5 (50–105;24.3)
Disease duration (months) 28 31.5 (4–180)
Medication
 Methotrexate, n (%) 28 16 (57.1)
 Prednisolone, n (%) 28 23 (82.1)
 Biologics naïve, n (%) 25a 15 (60.0)
Clinical parameters
 DAS28 (CRP) 28 4.61 (2.65–6.49; 1.75)
 Tender joint count (28-TJC) 28 7.0 (0–22;8.75)
 Swollen joint count (28-SJC) 28 2.5 (0–9;4.0)
 VAS patient (0–10 cm) 28 6.0 (2.4–10;3.0)
 VAS physician (0–10 cm) 28 4.0 (1.9–8.5;1.7)
 Morning stiffness (min.) 28 30 (0–240;63.75)
Laboratory parameters
 ESR (mm/h) 28 27 (8–66;21.0)
 CRP (mg/l) 27b 5.4 (0.3–52;17.4)
Fluorescence optical imagingc
 P1 28 1.5 (0–16;9.25)
 P2 28 19.5 (0–36;14.5)
 P3 28 1.0 (0–20;3.75)
 PVM 28 5 (0–27;6.25)
Musculoskeletal ultrasound (US7 Score)
 GS US7 synovitis (range 0–39) 28 11 (4–22;8.25)
 PD US7 synovitis (range 0–39) 28 2.0 (0–17;3.0)
 GS US7 tenosynovitis (range 0–5) 28 0.5 (0–3;1.0)
 PD US7 tenosynovitis (range 0–15) 28 0 (0–2;1.0)
  1. Data represent median (min–max; interquartile range) unless otherwise stated. aStatus for 3 patients unknown; bone sample not analysed; csum scores of both hands. DAS28 disease activity score of 28 joints, CRP C-reactive protein, VAS visual analogue scale, ESR erythrocyte sedimentation rate, GS grey scale, PD power Doppler, P phase, PVM prima vista mode, US7 ultrasound score of 7 selected joints